All News

Different Autoantibody Phenotypes in Juvenile and Adult Myositis A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.… https://t.co/fHL14rXAQ6 https://t.co/ZagRU62joJ
Dr. John Cush RheumNow ( View Tweet)
myositis.jpg

Different Autoantibody Phenotypes in Juvenile and Adult Myositis

d Jack Cush, MD

A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.

Read Article
RheumNow Podcast square

Systemic Sclerosis Insights (9.13.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
Consensus Guidelines on Pediatric Methotrexate Use MTX is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects: -indications and contraindications… https://t.co/6JtIMGOAhq https://t.co/OZJLqAyOnF
Dr. John Cush RheumNow ( View Tweet)
Methotrexate

Consensus Guidelines on Pediatric Methotrexate Use

d Jack Cush, MD

Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.

Read Article
Biomarker subanalysis of a phase 3 RCT of SC Abatacept in 219 polyarticular JIA pts. Lower baseline levels of S100A8/9 & S100A12 predicted better response (JIA-ACR90 2.5) at 16 mos. Decr in S100A8/9 & S100A12 @4mos was >50% among responders https://t.co/TWx62EhRBl https://t.co/6uhoRowg3n

Links:

Dr. John Cush RheumNow ( View Tweet)
Karolinska genotyping study of 329 JIA pts (oligo 161, Seroneg Poly 87, Seropos poly 12, Stills 24, ERA 22, PsA 19). HLA-DRB1*08 linked to JIA total; The HLA-DRB1*11 to Oligo; ANA+ JIA linked to HLA-DRB1-DQA1-DQB1, HLA-DRB1*11, & HLA-DPB1*02 https://t.co/1yNawNTEys https://t.co/dmmlH0CvRi

Links:

Dr. John Cush RheumNow ( View Tweet)
Gottrons,mechanics

Hispanic Patients With Dermatomyositis

d Jack Cush, MD

JAMA Dermatology has published a review of dermatomyositis (DM), focusing on similar and different manifestations of DM.

DM affects all races, but it has been suggested that racial and ethnic minority patients may have more severe disease and a different autoantibody profile. This analysis characterizes the clinical features and outcomes of DM in Hispanic and non-Hispanic patients.

Read Article
Full Read Overview of the safety of bDMARDs/tsDMARDS - contraindications, precautions, & boxed warnings for treatment of RA, PsA, SpA, JIA - safety checklist for a class of drugs you use and diseases you treat https://t.co/5chrS3sW8i https://t.co/twSv4Zs9r3

Links:

Dr. John Cush RheumNow ( View Tweet)
CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis CARRA has developed consensus treatment plans (CTPs) for the use of bDMARDs in patients with refractory, moderately severe juvenile dermatomyositis (JDM). https://t.co/NKikKGxlOY https://t.co/aJk8t5JTip

Links:

Dr. John Cush RheumNow ( View Tweet)
juvDM1.jpg

CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis

d Jack Cush, MD

CARRA has developed consensus treatment plans for the use of biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with refractory, moderately severe juvenile dermatomyositis. Juvenile dermatomyositis is the most common form of idiopathic, inflammatory myositis in childhood, with an estimated incidence of 3.2 per million children per year in the United States.

Read Article
US Childrens Hosp Admission database finds 8588 kids w/ SLE & ≥ 1 hospitalization; 13% for infections, w/ Bacterial pneumonia most common. cSLE In-hospital mortality in 0.4%, but 2% for infection. Highest mortality w/ PJP (21%), fungal infx (21%) https://t.co/fmyRXagCcD https://t.co/yXDMFYhhdP

Links:

Dr. John Cush RheumNow ( View Tweet)
New Classification Criteria for Juvenile Axial Spondyloarthritis An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA). https://t.co/kxtHlEk5XG https://t.co/jKAp9W5Di1

Links:

Dr. John Cush RheumNow ( View Tweet)
LBP.Child.juvenile.SpA

New Classification Criteria for Juvenile Axial Spondyloarthritis

d Jack Cush, MD

An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA).

Read Article
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/gvRzYpFl5i https://t.co/uSISWG3foy

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Future Big BiTEs (6.28.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.

Read Article
JAK Janus

New indications for JAK inhibitors

d Janet Pope, MD, MPH, FRCPC

There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.

Read Article
FDA has approved sarilumab (Kevzara) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg (138.891 lbs) or greater. https://t.co/b9NgyJVF2J https://t.co/cKoVxeBYIw

Links:

Dr. John Cush RheumNow ( View Tweet)
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @Yuz6Yusof https://t.co/eSqOkBGBK2
Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.